The 52-Week Low Club 8/28/2008 (GENR)(NRGN)
Williams-Sonoma (WSM) Profit drops. Down to $16.26 from 52-week high of $34.81. Nexmed (NEXM) Drug trial failure still pulling shares down. Dips to $.19 from 52-week high of $1.75. Genaera (GENR) Several clinical trials suspended. Falls to $.82 from 52-week…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Williams-Sonoma (WSM) Profit drops. Down to $16.26 from 52-week high of $34.81.
Nexmed (NEXM) Drug trial failure still pulling shares down. Dips to $.19 from 52-week high of $1.75.
Genaera (GENR) Several clinical trials suspended. Falls to $.82 from 52-week high of $3.09.
Neurogen (NRGN) Gets notice on Nasdaq delisting. Sells down to $.25 from 52-week high of $5.24.
Douglas A. McIntyre
Contact [email protected] for any questions or corrections.